

Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/CA3184784B5EN.html>

Date: May 2021

Pages: 48

Price: US\$ 125.00 (Single User License)

ID: CA3184784B5EN

Abstracts

Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on research, development and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, psoriatic arthritis and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics for and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer and seasonal influenza. Celltrion develops drugs by utilizing its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon, South Korea.

Celltrion Inc Key Recent Developments

Feb 22,2021: Celltrion achieved sales of KRW 1.84 trillion and operating profit of KRW 711.1 billion in 2020

Dec 01,2020: Takeda sells select products to Celltrion in Asia Pacific

Dec 01,2020: Takeda completes sale of select OTC and Non-Core Assets to Celltrion in Asia Pacific

Sep 25,2020: Celltrion Group Celltrion, Celltrion Healthcare, and Celltrion Pharmaceutical announced plans to merge three companies

Aug 07,2020: Celltrion achieved sales of KRW 428.8 billion and operating profit of KRW 181.8 billion in the second quarter

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Celltrion Inc - Key Facts
Celltrion Inc - Key Employees
Celltrion Inc - Major Products and Services
Celltrion Inc - History
Celltrion Inc - Company Statement
Celltrion Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Celltrion Inc - Business Description
Business Segment: Biopharmaceuticals
Overview
Performance
Business Segment: Chemical Medicines
Overview
Performance
Business Segment: Others
Overview
Performance
Geographical Segment: Domestic Market
Performance
Geographical Segment: Overseas Market
Performance
R&D Overview
Celltrion Inc - SWOT Analysis
SWOT Analysis - Overview
Celltrion Inc - Strengths
Celltrion Inc - Weaknesses
Celltrion Inc - Opportunities
Celltrion Inc - Threats
Celltrion Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Celltrion Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 22, 2021: Celltrion achieved sales of KRW 1.84 trillion and operating profit of KRW 711.1 billion in 2020

Dec 01, 2020: Takeda sells select products to Celltrion in Asia Pacific

Dec 01, 2020: Takeda completes sale of select OTC and Non-Core Assets to Celltrion in Asia Pacific

Sep 25, 2020: Celltrion Group Celltrion, Celltrion Healthcare, and Celltrion Pharmaceutical announced plans to merge three companies

Aug 07, 2020: Celltrion achieved sales of KRW 428.8 billion and operating profit of KRW 181.8 billion in the second quarter

Jul 28, 2020: Celltrion selects Movilitas for serialization and traceability implementations to ensure supply chain integrity and compliance

Jun 15, 2020: Celltrion to expand COVID-19 testing portfolio to include both antigen and antibody testing kits

Jun 12, 2020: Takeda to sell assets in Asia Pacific to Celltrion for \$266m

Jun 03, 2020: Celltrion-Punglim Pharmatech, selected as a national project for the development of insulin pen-type injections for 'Korean No.

May 27, 2020: Celltrion participates in the 'Incheon Startup Park' project

SECTION 6 – APPENDIX

Methodology

[Ratio Definitions](#)
[About GlobalData](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Celltrion Inc, Key Facts
Celltrion Inc, Key Employees
Celltrion Inc, Major Products and Services
Celltrion Inc, History
Celltrion Inc, Subsidiaries
Celltrion Inc, Joint Venture
Celltrion Inc, Key Competitors
Celltrion Inc, Ratios based on current share price
Celltrion Inc, Annual Ratios
Celltrion Inc, Annual Ratios (Cont...1)
Celltrion Inc, Annual Ratios (Cont...2)
Celltrion Inc, Interim Ratios
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Celltrion Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Celltrion Inc, Performance Chart (2016 - 2020)

Celltrion Inc, Ratio Charts

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/CA3184784B5EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA3184784B5EN.html>